TABLE 4

Base-case results (lifetime horizon#), intent to treat population

FF/UMEC/VIBUD/FORIncremental
Outcomes
 Predicted cumulative exacerbations
  Moderate exacerbations5.7935.804–0.011
  Severe exacerbations1.4221.434–0.012
 Any moderate and/or severe exacerbation7.2167.238–0.023
 Total LYs (discounted)9.0948.5610.533
 Total QALYs (discounted)6.6386.1320.506
Costs
 Maintenance£7531£8495–£965
 Moderate exacerbation£2459£2484–£25
 Severe exacerbation£6874£6974–£100
 Pneumonia£4261£3927£334
 Treatment£4887£3339£1549
 Discontinuation£404£641–£237
Total costs£26 416£25 860£556
 ICER per LY£1042Referent
 ICER per QALY£1098Referent

FF: fluticasone furoate; UMEC: umeclidinium; VI: vilanterol; BUD: budesonide; FOR: formoterol; LY: life year; QALY: quality-adjusted life year; ICER: incremental cost-effectiveness ratio. #: Outcomes and costs observed over the complete period (trial-based and Markov models).